SLC2A1 and familial pancreatic carcinoma: High glucose metabolism due to GLUT1/ALDOB/G6PD axis expression promotes drug resistance in pancreatic cancer, and inhibition of the GLUT1/ALDOB/G6PD axis may serve as a target for drug resistance therapy [34].